Serina Therapeutics reports Cohort 1 observations and advances to Cohort 2
Serina Therapeutics said it has reported Cohort 1 observations from its Ser-252 registrational study in advanced Parkinson’s disease and has advanced to Cohort 2.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Serina Therapeutics reports Cohort 1 observations from SER-252 study
Serina Therapeutics reports cohort 1 observations from its SER-252 registrational study in advanced Parkinson’s disease and advances to cohort 2.